STERIS is a global leader in infection prevention, contamination control, surgical technologies, and more.
STERIS is the world’s pre-eminent infection prevention, decontamination, and surgical and critical care company, with a long list of first-to-market products and industry-leading service innovations and thousands of customers in more than 60 countries.
While the corporation was founded as Innovative Medical Technologies in 1985 and renamed STERIS in 1987, our history dates back to 1894 with the founding of American Sterilizer Company, a long-time, global leading innovator of sterilization products.
Today, through a series of strategic acquisitions and continual innovation of new products, STERIS holds one of the broadest portfolios of products in the industry. It stands at the forefront of efforts to prevent infection and contamination in healthcare and pharmaceutical environments, and is broadening its reach with products to meet the needs of defense and industrial markets.
STERIS Office Locations
STERIS Data and Metrics
STERIS Financial Metrics
Revenue (FY, 2017) | 2.6 b |
Revenue growth (FY, 2016 - FY, 2017), % | 17% |
Gross profit (FY, 2017) | 1 b |
Gross profit margin (FY, 2017), % | 39% |
Net income (FY, 2017) | 110 m |
EBIT (FY, 2017) | 227.6 m |
Market capitalization (21-Jul-2017) | 7 b |
Cash (31-Mar-2017) | 282.9 m |
- Source: SEC Filings
| USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|
Revenue | 1.6 b | 1.9 b | 2.2 b | 2.6 b |
Revenue growth, % | 14% | 21% | 17% | |
Cost of goods sold | 972.6 m | 1.1 b | 1.3 b | 1.6 b |
Gross profit | 649.6 m | 774.3 m | 895.5 m | 1 b |
Gross profit Margin, % | 40% | 42% | 40% | 39% |
R&D expense | 48.6 m | 54.1 m | 56.7 m | 59.4 m |
Operating expense total | 442.8 m | 547.1 m | 682.6 m | 798 m |
EBIT | 206.8 m | 227.2 m | 212.9 m | 227.6 m |
EBIT margin, % | 13% | 12% | 10% | 9% |
Interest expense | 18.8 m | 19.2 m | 42.7 m | 44.5 m |
Income tax expense | 58.9 m | 73.8 m | 60.3 m | 74 m |
Net Income | 129.4 m | 135.1 m | 110.8 m | 110 m |
- Source: SEC Filings
| USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|
Cash | 152.8 m | 167.7 m | 248.8 m | 282.9 m |
Accounts Receivable | 313.7 m | 325.3 m | 471.5 m | 483.5 m |
Inventories | 37 m | 35 m | 59.4 m | 197.8 m |
Current Assets | 674.7 m | 720.4 m | 972.5 m | 1 b |
PP&E | 454.4 m | 493.1 m | 1.1 b | 915.9 m |
Total Assets | 1.9 b | 2.1 b | 5.3 b | 4.9 b |
Accounts Payable | 102.4 m | 99.3 m | 139.6 m | 133.5 m |
Current Liabilities | 254.5 m | 283.3 m | 400.6 m | 381.6 m |
Total Liabilities | 2.1 b | |||
Retained Earnings | 1.1 b | 1.2 b | 939.5 m | 954.2 m |
Total Equity | 1 b | 1.1 b | 3 b | 2.8 b |
Financial Leverage | 1.8 x | 2 x | 1.8 x | 1.8 x |
| USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|
Net Income | 129.4 m | 135.1 m | 110.8 m | 110 m |
Accounts Receivable | (29 m) | (2.8 m) | (31.6 m) | (48.1 m) |
Accounts Payable | 19.4 m | (3.1 m) | 5.2 m | 6.9 m |
Cash From Operating Activities | 209.6 m | 246 m | 81.2 m | 424.1 m |
Cash From Investing Activities | (148.7 m) | (283.8 m) | (729.6 m) | (104.3 m) |
Long-term Borrowings | (70 m) | (92.6 m) | (172.5 m) | |
Cash From Financing Activities | (54.2 m) | 69.8 m | 560.3 m | (267.1 m) |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 186.6 k |
Financial Leverage | 1.8 x |
